Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P47871: Variant p.Asp63Asn

Glucagon receptor
Gene: GCGR
Feedback?
Variant information Variant position: help 63 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Aspartate (D) to Asparagine (N) at position 63 (D63N, p.Asp63Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (D) to medium size and polar (N) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In MVAH. Any additional useful information about the variant.


Sequence information Variant position: help 63 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 477 The length of the canonical sequence.
Location on the sequence: help CHHNLSLLPPPTELVCNRTF D KYSCWPDTPANTTANISCPW The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         CHHNLSLLPPPTELVCNRTFDKYSCWPDTPANTTANISCPW

Mouse                         CHHNLSLLPPPTELVCNRTFDKYSCWPDTPPNTTANISCPW

Rat                           CHHNLSLLPPPTELVCNRTFDKYSCWPDTPPNTTANISCPW

Pig                           CLRNLSLLPPPTELVCNRTFDKYSCWPDTPPNTTANISCPW
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 26 – 477 Glucagon receptor
Topological domain 26 – 136 Extracellular
Glycosylation 46 – 46 N-linked (GlcNAc...) asparagine
Glycosylation 59 – 59 N-linked (GlcNAc...) asparagine
Glycosylation 74 – 74 N-linked (GlcNAc...) asparagine
Glycosylation 78 – 78 N-linked (GlcNAc...) asparagine
Disulfide bond 43 – 67
Disulfide bond 58 – 100
Mutagenesis 63 – 63 D -> A. Abolishes glucagon binding.
Mutagenesis 65 – 65 Y -> A. Strongly reduced affinity for glucagon. Increased constitutive signaling via G-proteins.



Literature citations
Hypercalcemia in glucagon cell hyperplasia and neoplasia (Mahvash syndrome): a new association.
Gild M.L.; Tsang V.; Samra J.; Clifton-Bligh R.J.; Tacon L.; Gill A.J.;
J. Clin. Endocrinol. Metab. 103:3119-3123(2018)
Cited for: VARIANT MVAH ASN-63;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.